Latest News

Alectinib exhibited a CNS DFS improvement, with a 63% reduction in the risk of this event, and 4-year CNS DFS rate was 90.4% vs 76.1% with chemotherapy.
Adjuvant Alectinib Exhibits Sustained Survival Benefit in ALK+ NSCLC

October 20th 2025

Alectinib exhibited a CNS DFS improvement, with a 63% reduction in the risk of this event, and 4-year CNS DFS rate was 90.4% vs 76.1% with chemotherapy.

Retrospective cohort findings may inform tailored treatment approaches for frontline metastatic BRAF V600E-mutated non–small cell lung cancer.
Frontline Immunotherapy Improves OS vs BRAF/MEK Inhibitors in BRAF+ NSCLC

October 20th 2025

Data from the KEYNOTE-671 trial support the use of pembrolizumab among patients with non–small cell lung cancer in the perioperative setting.
Survival Improves With Perioperative Pembrolizumab in Early-Stage NSCLC

October 20th 2025

Data from the phase 3 HARMONi-6 study may support ivonescimab plus chemotherapy as a new standard of care in advanced squamous non–small cell lung cancer.
Ivonescimab Combo Boosts PFS in Advanced Squamous NSCLC Trial

October 19th 2025

Slow accrual led to the early stopping of the phase 3 DREAM3R trial assessing durvalumab/chemotherapy in advanced pleural mesothelioma.
Durvalumab Combo Shows Consistent Outcomes in Advanced Pleural Mesothelioma

October 19th 2025

Video Series
Video Interviews
Podcasts
Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.
Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.
Latest CME Events & Activities

More News